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The new immunosuppressive agent FK 506 was used as 
primary immunotherapy in conjunction with low-dose 
steroids and azathioprine in 72 patients subsequent to 
orthotopic cardiac transplantation. Overall patient sur· 
vival at a mean follow-up of 360 days was 92%. The 
number of episodes of cardiac rejection (grade 3A or 
greater) within 90 days of transplantation was 0.95 per 
patient. The actuarial freedom from rejection at 90 days 
was ~ 1 %. Achievement of this level of immunosuppres-
sion is comparable with that of cyclosporine-based tri-
ple-drug therapy with OKT3 immunoprophylaxis. Thirty 
percent of patients were tapered off all steroids, and the 
average steroid dose in the group who received steroids 
The potent immunosuppressive macrolide antibiotic FK 306 has undergone clinical testing at Presbyterian-
Uni\'ersity Hospital since January 1989. The initial clinical 
trials were designed for liver transplant recipients with 
refractory rejection 11. 2), and pursuant to the dramatic 
and gratifying results. FK 506 was introduced as the basis 
of immunosuppression in kidney and liver transplant 
reCipients in March 1989 [3. -i), Since October 1989. in a 
prospective clinical trial. 7:! patients have undergone 
vrthl1!OplC cardiac transplantation rpfn~ primarilv FK 506 
.lnll low-dose sterOIds as ImmunosuppressIOn, Dramatic 
results were also attained In 10 patients With cardiac 
relectlOn .lclractorv to "Ii known com/entlonal treatment 
\\'hll underwent rescue therap\' With FK 506, 
Material and Methods 
Primary PaliCllt GrollI' 
Sewntv-two patients were prospecti\'ely entered into this 
,Iud\' irom October 19R9 to Januarv 1992. Informed con-
'l'lll W.1S obtained from each patient before transplanta-
I:on tor the use of FK 506 and sterOids as the foundation 
,'I Immunosuppressive therapy; 10 patients received con-
\'l'ntlonal cvclosporine-based ImmunosuppreSSIOn dunn~ 
thi~ pCl'lod_ These 10 patients either had hemorrha~e or 
hl'mlldvnamlc problems that precluded the initiation 01 
Flo.: 306 therapy Within O~ hours oi transplantation or 
iDDDD~nlrd .llhe qwenls~~hlh Annu.l MfDrhn~ 01 qh~ poo~fs 01 Thor.Clc 
Sun: .... n'. Orundo. Fl. Ft'b }OS. 1992. 
'JJ ... " ... .,nnl rt'qU"I' 10 Dr Annll~KeK o".,.rtml'nl 01 Surs:en', L'nl\'rr-
-,l\ .. , PllIsburS:h. IllIW Sell'le e~ffK millst>u~lfK PA 15261. 
: oq:! b\' The s..lC1erv ot Thorlac SUrJl:eon!l 
was 8.6 mg of prednisone per day. The incidence of 
infection reflected the diminished necessity for steroids: 
seven major infections (10%) and 11 minor infections 
(l6%). Renal dysfunction occurred during the perioper-
ative period in most patients in this trial. However, the 
incidence of hypertension was 54'7.: compared with 70'7.: 
during the cyclosporine era. Ten adults underwent suc-
cessful rescue therapy with FK 506 after cardiac rejection 
refractory to conventional immunotherapy. Side effects 
of FK 506 were notably few, and the results of the trial 
are encouraging for the future ot the cardiac transplant 
recipient. 
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refused consent. No attempt was made to selectively 
enroll patients in this study based on severity of illness. 
preoperative United Network for Organ Sharing status. or 
preoperative end-organ function. 
In the study group. there were 59 men and 13 women 
ranging in age from 2-1 to 61 years. Eight patients (117<) 
required mechanical circulatory support before transpl.1n-
lation in the form oi the Novacor left ventricular assist 
device (6). the Thoratec left "entncular assist device (1). 
,md a total arhhcial he.nt (1), Six other patients aw.'lted 
transplantation With intraaortlc bJlloon pump support. 
The CJuse of cardiom\'opathv Included ischemiC (32). 
idiopathiC (23). valvular (6). myocarditis H). hvpertrophic 
(3), retransplant.1hon (31. .lnd congenital heart disease (I), 
Panel reactiVt.' .1Otibod\· was less than 1O'7r in all but 3 
patients. Mean iollow-up \\'.1S 360 d.1\'S (range, 3 to 827 
days) .15 oi J.,nu,uv 1992. 
Resellt' Palit'II1 Grollp 
fhe cnteria ior the use 01 FK 506 as a "rcscue" .'gent wcrt' 
strictly dependent on pl.'rsistent grade 3A reJl'ctlOn and 
prevIous treatment with triple-drug therapy (cvclospo-
rine. azathiopnne. and sterOids) and conventional rescue 
therapy for relechon oi at least two courses of intravenous 
sterOids and one or more courses' oi antilvmphocvte 
therapy (antithvmocvte globulin. antllvmphocvte globu-
lin. or OKT3). 
The 10 patients In the rescue group represented an 
extremelv heterogeneous population. Six of them were 
reierred to our inStitution from other centers. They were 
younger (age range, 22 to 50 years I and were seen earlier 
after transplantation (range, 3 to 22 months; average. 8 
00034975'92'55.00 
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months) than those from our own center. All 6 patients 
referred for FK 506 rescue had refractory grade 3A or 
greater rejection and had received at least one course of 
OKT3 and two courses of intravenous methylpredniso-
lone. Three of the 6 had received both antlthvmocvte 
globulin and OKT3. One patient had had two course~ of 
antithymocyte globulin and one course of OKT3. Another 
patient had had a course of methotrexate. All of these 
patients were receiving high-dose cyclosporine. azathio-
prine. and prednisone. 20 to 50 mg/day. One patient had 
had a panel reactive antibody of 60% before transplanta-
tion. had acutely rejected the first transplanted heart. and 
was supported on extracorporeal membrane oxygenation 
for a week before retransplantation. She then had persist-
ent rejection of the second heart and was referred for 
rescue. 
The 4 patients from our center (age range. 53 to 67 
years) had undergone transplantation 1 year to 4 years 
previouslv (average time. 2.5 years). All had received one 
to two courses of antithymocyte globulin and one to two 
attempts at steroid therapy and had persistent grade 3A 
relection. 
F K 506 Therapy 
FK 506 treatment was begun as an intravenous loading 
dose within 6 to 12 hours after transplantation. In the 
early clinical trial. from October 1989 to August 1990. 23 
patients received 0.15 mg' kg-I. day-I of FK 506 in two 
divided doses. each over 4 hours. for a duration of 24 to 72 
hours. As soon as gastrointestinal function returned. oral 
FK 506 was initiated at a dose of 0.3 mg • kg - I . day - I. 
with the first oral dose given with the last intravenous 
dose. Since August 1990. 49 patients have received 0.05 
mg . kg - I . day -I of FK 506 as a continuous intravenous 
infusion as a loading dose begun within 6 to 12 hours after 
transplantation for 24 to -t8 hours. Oral administration of 
FK 506 was begun at 0.3 mg' k~-fK day-I Jfter the 
Intravenous infusion was completed. The oral dose 01 FK 
506 was' targeted for a serum level of 0.7 to 1.5 ng/mL 
(12·hou'r trough enzvme-linked immunosorbent assav by 
the technique of Tamura and colleagues (5)) depending on 
renal function and rejection historv. The oral maintenance 
dose to ,1ttain target Il'\,els ranged from O.().l to OA 
mg' kg -I . day -I With .1n avera~e oral dose of 0.15 
mg . kg - 1 • day I, 
Slam" TTlafll'Y 
\lethvlprednisolone. ;- tll 10 mg'kg. was administered 
Intravenously in the operatmg roum and in three divided 
doses ior a total of 5 mg/kg in the iirst 24 hours after 
transplantation. Therealter. patients received oral pred-
nisone. 0.15 mg • kg -I , day - I, In the early trial (October 
1989 to August 1990). steroid weanmg was begun at the 
llrst week after transplantation based on ireedom from 
relectlOn. Since August 1990. steroid weaning has begun 
Jt the 12th posttransplant week. again based on freedom 
from relection. 
Otlltr A~ellts 
Azathiopnne was reserv~ as an adjunctive immunosup-
pressIVe agent to aid in control of rejection or to allow 
Ann Thnfil(' pu~ 
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lower FK 506 treatment in patients with renal dvsfunc-
tion. OKT3 was reserved for severe rejection ass"aciated 
with hypotension or hemodynamiC compromise. 
All patients entered into the FK 506 immunotherapy 
protocol were placed on a regimen of prophylactic oral 
trimethoprimisulfamethoxazole and nystatin (Mycostatin; 
E.R. SqUibb & Sons, Princeton. NJ). Acvclovir was admin-
istered for the first 6 months aiter t~ansplantatlln and 
discontinued thereafter. 
FK 506 Rescue Therapy 
"Rescue" treatment required a 7- to 14-day hospitaliza-
tion. The medical records and endomyocardial biopsy 
slides of the patients were reviewed. and complete blood 
screening as well as chest and abdominal computed 
tomographic scans were performed. Cyclosporine admin-
istration was discontinued the day of admission. and in 8 
of the 10 patients. azathioprine was also discontinued. 
Steroid dose was diminished to half the maintenance 
dose. No intravenous loading dose of FK 506 was admin-
istered. The patients were begun on a regimen oi oral FK 
506, 0.3 mg • kg -I • day - I, in two divided doses. and FK 
506 levels were targeted at 1 to 1.5 ngimL. Cardiac 
function was evaluated by multigated acquisition scan 
and echocardiography before and after FK 506 rescue. An 
endomyocardial biopsy was performed on day 7. If rejec-
tion had resolved by day 7, the patient was discharged 
and followed· with endomyocardial biopsy. echocardiog-
raphy. blood work. and measurement of FK 506 levels. If 
rejection had not resolved at the time of the first biopsy. 
the patient had a second biopsy on day 14. All rescue 
patients were discharged home within 14 days. 
Mlllitvrill~ jor Rl?jcctioll 
Surveillance of all pallents after transplantation involved 
weeklv transvenous l!ndomvocardial biopSIes dunng hos-
pitalization and at slowlv increased intervals alter dis-
char~eK Biopsy specimens were graded using hematoxylin 
and eosin staining after light mICroscopy by a pathologist 
who was blinded to the immunosuppressive protocol of 
the patient. Biopsy grades were ddined accordmg to the 
standardized nomenclature ior cardiac relectlon [6). Bi-
upsy specimens that were read bdore the advent oi the 
standardized nomenclature were retrospectively re-
viewed and graded according to the new stand.udized 
method. 
MOllitoring jor l"fectivlI 
All patIents were followed up bv a specialist in Infectious 
disease. Titers tor hepatitis B virus. herpeSVirus. Epsteln-
Barr vIrus. human immunodeficiency virus. T,lxoplasma. 
and cytomegalovirus were performed on aU donors and 
reCIpients before transplantation. The diagnosis of infec-
tion was made using clinical criteria as previouslv defined 
by this institution [7]. Complete blood screentng was 
performed dailv in the hospital and at aU (ollow-up Visits. 
Questlonnaares to identity untoward side effects ot FK 506 
were completed on aU patients throughout tollow-up. 
Ann Thorac Surg 
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Results 
Survival 
Sixty-six (92%) of the 72 patients entered into this trial are 
alive. The perioperative mortality (30 days after transplan-
tation) was 4%. The causes of the 3 early deaths were as 
follows: secondary to pulmonary hypertensiOn/right heart 
failure; disseminated aspergillosis; and unknown. The 
patient with an unknown cause died suddenly on. an 
exercise CYcle at home; he had had no epIsodes of reJec-
tion at fo~r biopsies; permission for postmortem exami-
nation was denied. 
The late mortalit\· (>30 days after transplantation) was 
4%. The first late ·death w~s secondary to low cardiac 
output (day 54); there was no evidence of rejection. 
cellular or humoral. or serious coronary artery disease at 
postmortem examination. The second late death was due 
to pneumonia. empyema. and colitis (month 6), and the 
third. to mvocardial infarction and coronary arteriopathy 
after gratti~g (month 10). No death has been attributed to 
FK 506 therapy or to acute or refractory cardiac reJection. 
Rejection 
Rejection was defined as any histological diagnosis of 
grade 3A or greater. An episode of reJection was defined 
as one biopsy grade of 3A or greater. irrespecttve of 
sequential occurrence. Recurrent rejection was defined as 
a biopsy grade of 3A or greater after treatment and 
resolution of a prior episode of rejection. 
[n the primarv therapy group there were 72 patients. 67 
of whom were followed up for 90 days or more. We 
analyzed this group as a whole and also as two groups 
based on the FK 506 intravenous induction dose: group I. 
0.15 mg·kg-I·day-I (n = 20), and group 2, 0.05 
mg' kg-I. dav- I (n = 47). 
Of these 67 patients. 33% never had an episode of 
reJection. and 67% had at least one episode. The mean 
number ot days to the first episode of reJection was 37 :: 
52 (median. i6 days; range, 6 to 237 days). The mean 
number ot episode~ of rejection per pattent within 90 days 
was 0.95 :: 1.01 (median number. 1). Recurrent rejection 
occurred in 27.6% oi the total group. The actuarial free-
dom from reJection at 90 days was 41 % and at 180 days, 
:>4% (Table 1). 
The high-dose (0.15 mg' kg -I • day -I) FK 506 induc-
tion group \group 1) was analvzed and compared with the 
low-dose (0.05 mg . k~ - I • day -I) group (group 2). The 
Tllblt l. n: 506 Va, lIS uhqP/qrilD/ED-ar/l~ 
IIIImunoSIlIlIIrt·,Sj(l1/ 
lhnqripl~ 
Vanabll.' 
Ml.'ln hme to IIrst grad~ 3 r~iectlon (d) 
mlKD~nt rl.'le<"tlon In'l.' dl 'JO days 
Rl.'il.'Ctton I.'pISOOes.pJUCnIS 011'90 d.1\'s 
me~nta~e \Yllh rlocurrenl relt.'Ctlon 
Drug 
(n ·43) 
33 !: 5.6 
~ 
-h'I 
FK 506 
(n • !l7) 
37 !: 52 
41 
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Table 2. Low-Dose Versus High-Dose FK 506 
[mmu nosu ppressioll'l 
Variable 
Mean time to first grade 3 rejection (d) 
Percent rejection iree at 90 days 
Rejection episodeplpatl~nts at 90 days 
Percentage with recurrent relection 
Group 1 
(n = 20) 
3-1 
40 
0.95 
20 
Group 2 
(n = 47) 
14b 
41 
0.95 
31 
• Group 1 received 0.15 mg • k~ . I • day - I and group 2. 0.05 mg • kg - I . 
day-I. " SigOilicanCl.!: " < ll.OI. 
actuarial freedom from rejection at 90 days was 40% 
versus 4IIk, respectively. Statistical analysis failed to 
reveal any significant difference between the two groups 
In the va~iables of rejection studied with the exception of 
the mean number of days to the first episode of rejection 
(Table 2). 
Twentv-one (3IIk) of the 67 patients had FK 506 as the 
onlv imritunosuppressi\'e agent. Thirty-mne (58%) were 
giv~n prednisone (5 to 10 mgldayl. and 28 (42'iC) reqUIred 
azathioprine. Twenty-one patients (317r) were on a regi-
men of triple therapy (FK 506. azathiopnne. and pred-
nisone). Only 3 patients (4%) required OKT3 for severe 
rejection. 
Seven of the 10 patients in the rescue group were free 
from rejection after the FK 506 switch. The other 3 each 
required one subsequent treatment to resolve rejection: I 
received a prednisone taper; I. an intravenous dose of 
methylprednisolone for 3 days; and 1. intravenous meth-
ylprednisolone and OKT3. The average length of f~l­
low-up in this group was 11 months. The average mam-
tenance dose of FK 506 in the rescue group wa.s 0.12 
mg • kg -I • day -I. Eight of the 10 patients remained on a 
regimen of steroids but at considerablv lower doses; the 
average prednisone dose was 20 mglday before rescue 
and 7.5 mglday after rescue. Four patients were treated 
with azathioprine and FK 506. 3 of whom were also 
receiving prednisone. 
Infectioll 
Four major infections were present in 3 patients before 
cardiac transplantation. One pattent had two infections 
before transplantation: staphylococcal line sepsis second-
arv to an intraaortlc balloon pump and sternal Camiltia 
os·teomvelitis at the time of removal of a Novacor left 
ventric~lar assIst device. This same patient hOld pulmo-
narY emboli and iniarctlOns before placement of the 
dev"ice but remaanl'd free irom antl'Ctlon alter transplanta-
tion With FK 506 as the sole immunosuppressive agent. 
Amphoterrctn was administered lor :; weeks .liter trJns-
plantatIOn. ,lnd the palumt recovered WIthout sequelae. 
The second patient hOld .J KldlSldla pneumoOlJ durrng 
intraaortlC balloon pump support. received 8 days of 
Jntibiotic therapy before transplantation . .lnd rt'covered 
WIthout iurther miectlon. The third F'Jltent WIth In Inlec-
tion before transplantatIon had endocarditis .md line 
sepsis WIth sterile blood cultures be/ore trolnspl.tntatlon. 
He also recovered without cllmphcoltlOns. 
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After transplantation. there were 18 infections in the 67 
patients followed up for 90 days or more. There were 
seven maJor infections (10%) in 5 patients. with two 
deaths secondarY to infection; one was due to dissemi-
nated aspergillosis and one, to a gram-negative pneumo-
nia/empyema with subsequent ClostridiuIII difficilt colitis. 
One patient had a pulmonary abscess and subsequently 
had development oi an aortic suture line mvcotic aneu-
rysm. which was diagnosed by magnetic reso'nance imag-
ing and repaired. Another patient had two pneumomas, 
pneumococcal and pneumocystlc. The seventh major in-
fection was a Proteus and staphylococcal abdominal 
wound infection after explantation of a Novacor left 
ventricular assist device. There were 11 (16%) minor 
infections, six of which were gastrointestinal cytomegalo-
virus. 
In the rescue group, 5 (50%) of the 10 patients had 
infections before or at the time of the FK 506 switch. Two 
patients had cytomegalovirus and herpetic infections, 3 
had cytomegalovirus alone, and 1 patient had a ruptured 
aortic suture line Salmoneila mycotic aneurysm. Subse-
quent to FK 506 rescue, there were three infections: 
bronchitis, gastritis, and pneumonia. 
Cardiac Function and Coronary Arteriopathy 
All surviving patients had exceUent cardiac function. In 
the primary patient group, the average left ventricular 
ejection fraction measured by gated nuclear scan, echo-
cardiography, or both was 0.66. The range was 0.48 to 
0.75 at the time of longest follow-up. The average left 
ventricular ejection fraction in the rescue group was 0.61 
(range, 0.47 to 0.70) before the switch and 0.63 (range, 
O.SO to 0.76) after rescue. 
Coronary arteriopathy after transplantation was de-
fined as any luminal irregularity or any degree of coronary 
stenosis. To maXimize the pOSSibility 01 detecting coro-
nary disease transplanted from the donor to the reClpient. 
any reCipient of a donor heart 40 years or older had 
coronary angiography before discharge alter the trans-
plant procedure. There were 4 such patients. and all the 
coronary studies were normal. The average donor age 
was 33 years (range. 19 to 49 years). At the I-year-
follow-up interval. 35 patients have undergone routine 
left and right heart catheterization with coronarY angiog-
raphy. and 4 patients (11 ~F have had posttransplantation 
coronarY arteriopathv. There was one death due to mvo-
cardial infarction In a patient With detected coron~rv 
disease at 1 year. 
Renal Functioll aud HY1Jerte//slOlI 
In the 67 patients followed up for 90 davs or more. the 
mean creatinine level belore transplantation was 1.3 
ngtdl (:: 0.8) and at 3 and 6 months alter transplantation, 
1. 9 ngldL (:: 0.7) and 2.2 ng/dL (:: 0.5). respecuvelv. In 
group 1. With high-dose intravenous Induction. the mean 
pretransplantation creatinine level was 1.4 ngJdL and at 3 
and 6 months after transplantation. 2.3 ngldL. In group 2. 
With lower dose mtravenous FK 506 induction, the mean 
pretransplantation creabnine level was 1.3 ngJdL and at 3 
and 6 months after the procedure, 1.B ngtdL and 2.1 
.-\nn Thorac ~ 
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ngidL, respectively. Although there was no Significant 
difference in serum creatmme level between the two 
groups. 4 patients required dialvsis in the perioperativ@ 
period, 3 of whom were in group 1. Peak renal dysfunc_ 
tion occurred at the first postoperative week with an 
average serum creatinine level of 2.3 ngldL (:: 1.03). In 
the rescue group. the switch to FK 506 was very Well 
tolerated with respect to renal dysfunction. The average 
serum creatinine level was 1.3 ngldL before rescue and 18 
ngidL after rescue. 
Thirty-six (54%) of the 67 patients had diastolic hyper-
tension necessitating antihypertensive therapy. All 36 
patients were treated with a single agent, either enalapril 
maleate or diltiazem hydrochloride_ In the rescue group, 7 
of the 10 patients had hypertension before rescue, and all 
7 continued to require treatment while receiving FK 506. 
However, 2 of the 7 patients were able to control the 
hypertension with single-drug as opposed to double-drug 
therapy on a regimen of cyclosporine. 
Metabolic Studies a11d Side Effects 
There were 20 insulin-dependent diabetics among the 67 
patients receiving primary FK 506 therapy after cardiac 
transplantation. Four of the 20 were insulin dependent 
before transplantation (2 had juvenile-onset diabetes mel-
litus), and 3 were non-insulin-dependent diabetics. There 
were 12 new-onset insulin-dependent diabetic patients 
(20%) among 60 nondiabetic reCipients. Ten of the 12 with 
new-onset diabetes were also on a regimen of prednisone 
(average dose, 7 mgJday). 
Continued monitoring of hematological and coagula-
tion indices as well as hepatic function failed to rl'veal any 
abnormalities at this follow-up interval. Cholesterol and 
triglyceride levels have been slightly lower than those In 
cydosponne-treated patients. but not slgnllicantlv so. 
Five patients have borderline elevated unc aCid levels. 
Elevated serum potassium levels (K + > 5.0 mEqil). which 
reqUired treatment With furosemide. were seen in 8 pa-
tients. This abnormality in K - excrellon was lOde pendent 
of renal function and has been observed in other organ 
recipients treated with FK 506. 
Side eifects have been rare despite routme ljuestlon-
naires during hospitalizatIOn and during outpatient tol-
low-up. There have been no seizures. cerebrovascular 
accidents. or neuropathies secondarY to FK 506. One 
patient In the pnmary therapy group had a thromboem-
bolic oCCIpital cerebrovascular aCCIdent With aSSOCiated 
hemorrhage and seizure from which he has recovered 
with little reSidual deficit. There have been occaSional 
reports of extremity parestheSia and temperature malsen-
sations. usually associated wuh elevated FK 506 levels. 
One patient ~ith mild multiple sclerosis expenenced 
akinetic rr.utism while receiving FK 506, which led to a 
reduction In the dose. He has smce recovered and re-
turned to work. Muscle aches. mild insomnta. and tremor 
were also reported. Notably absent in this patient group 
were complaints oi gingIVal hvperplasla or hirsutism_ 
Ann Thorae Surg 
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Posttranspiantation Lymphoproliferative Disease 
Ten months after transplantation. 1 patient (1.4%) in the 
primary therapy group had development of an inflamma-
tory cervical adenopathy. which on excision biopsy was 
consistent with posttransplantation Iymphoproliferative 
disease. Reduction in immunotherapy resulted in resolu-
tion of the process. and no recurrence has been detected 
at 16 months' follow-tlp_ Two months after rescue. 1 
patient in the rescue group also had posttransplantation 
Iymphoproliferative disease. which manifested as gastro-
intestinal hemorrhage necessitating laparotomy. Again. 
reduction in immunotherapy led to resolution of the 
disease process. Her immunosuppression regimen before 
rescue had consisted of four courses of intravenous ste-
roids and OKT3 with cydosporine. azathioprine. and 
prednisone over a 2-month period. 
Comment 
These earlv results with FK 506 as the basis of immuno-
suppression hold tremendous promise for the future. 
both as pnmary immunotherapy in cardiac transplanta-
tion and as an effective agent for rescue therapy in 
refractory cardiac rejection. In a prospective. randomized 
study (8) performed at the University of Pittsburgh com-
paring rabbit antithymocyte globulin with OKT3 immu-
noprophylaxis plus cyclosporine-based triple-drug ther-
apy, the OKT3 immunoprophylaxis group had an 
actuarial freedom from rejection at 90 days after trans-
plantation of 40% with 1.0 episode of rejection per pa-
tient. The actuarial freedom from rejection in the FK 506 
and low-dose steroid immunotherapy group at 90 days 
after transplantation in our study was 41% with 0.95 
episodes of reJectlon per patient. However. the percent-
age of recurrent relection was 48% With OKn/cyciospo-
nne versus 28% With FK 506 (p < 0.01. i analysis). 
We have been Impressed with the abilitv oi this new 
agent to attain immunosuppression In cardiac transplant 
reCIpients comparable with one of the best immunosup-
preSSive protocols at the University of Pittsburgh during 
the last decade. This level of immunosuppression has 
been achieved without antilymphocyte therapy. without 
immunoprophylaxis. <lnd with marked reduction in ste-
rOid and azathiopnne requlrements. Twenty-eight (42%) 
of the 67 patients In this study who were followed for 90 
days or more receive no steroids at .111. The average 
steroid dose tor those adults on a regimen of prednisone 
IS 8.6 mgldav. The! dramatic abilitv ot FK 506 to reverse 
cardiac relechon that has bccn rcfracton' to aggressive 
treatment With (Onvcntlonal immunotherapeutic tools 
and the rciatlvelv low rate 01 malor (10'l) <lnd minor (Ib'h-) 
Intectlons are turther testament to the potcnt.-Y <lnd selec-
tiVity ot Its Immunosuppressive actions. 
Another advantage 01 FK 506 is the tlexibilitv It intro-
duces to Immunosuppressive management. Mild to mod-
erate reJection (grades I A. I B. and 2) was trCJtL-d prctcr· 
entiaUv bv merelv fncreasln~ the FK 500 dost'. fhe 
concept 01 au~me~tgn~ Immunosuppression and treatm~ 
rejec:tton bv tncreastn~ baseilne Immunotherapy .1dds a 
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new tool to our armamentarium of antirejection therapy. 
The biological and immunolOgic basis for this quality of 
FK 506 is presently under intense study at the University 
of Pittsburgh. Despite the immunosuppressive potency of 
FK 506. the incidence of early posttransplantation lym-
phoproliferati\'e disease (1.4%) in the cardiac recipient is 
similar to the incidence (1.8%) observed in the previous 
decade of c\'closporine-based immunotherapy (9). 
Despite the excellent tolerance of FK 506 by patients 
and few obser\'ed or reported side effects. renal dysfunc-
tion is a price paid when the drug is used as described in 
this report. \\' e believe that systematic overdosing oc-
curred in patients receiving FK 506 intravenously in the 
perioperath'e period in our attempt to achieve high early 
FK 506 levels (group 1). We have changed initial bolus 
intravenous FK 506 therapy to continuous Infusion and 
have lowered the initial intravenous dose to a single 
24-hour constant infusion dose at 0.05 mg!l<g. with enteral 
FK 506 begun on the first postoperative day (group 2). 
Attendant With reduction of the postoperative .i'ntrave-
nous loading dose of FK 506. the median time to first 
grade 3A rejection was diminished from 34 to 14 days. 
We belie\'e that the intravenous induction dose is 
important to gain appropriate early downregulation of the 
immune system. Further refinements in our knowledge 
regarding FK 506 dosage and therapeutic levels. together 
with the diminished incidence of hypertension. may 
actually improve the long-term outlook for renal function 
in cardiac transplant recipients. The incidence of hyper-
tension was 54% in the FK 506 group versus 70% in the 40 
cardiac transplant recipients at the University of Pitts-
burgh before October 1989. 
FK 506 does have a negative effect on the beta islet cell. 
and this is retlected in the 189'0 incidence of new-onset 
diabetes in the adult population. This diabetogemc effect 
was enhanced by the necessity for steroid therapy In 10 of 
these 13 patients. 
As cyclosponne had little impact on the manifestation 
of chromc allograft rejection or coronarv artenopathy. the 
full impact of FK 506 has yet to be determtned. The i-year 
incidence of coronary artenopathy was 11 %. Until we 
improve our understanding oi the mechanisms and 
immunobiology of this process and are able to target 
different arms of immune upregulation. posttransplanta-
tion coronan' .lrteriopathv Will contmue to occur at a 
predictable rate and threaten the lon~-term survival of the 
(ardiac transplant reCIpient. 
Cardiac lunctlon and the quality of life (101 in our 
patient ~roup have bt!en excellent. Cuncerns re~arding 
\'.1sculitis .1nd neuropathy have not bt'en realized. The 
Jimimshcd n~ed for steroids. nonspl'Clfic bone marrow 
suppression. and antilymphocvte and antlhvpertensive 
therapy holds tremendous promise for the future of 
cardi.1c transplant reapients. 
~~f thank~ lur olsslstolnno to Ann Let'. Di ... n .. ZJI.Junls. Wl"ndv 
lJorwto. ::iharon Burk~ltl"K and Muv HutchIson. 
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DISCUSSION 
DR R. MORTON BOLMAN III (Minneapolis. MN): The Pitts-
burgh group has made many contnbutions over the last 10 years 
in the held of heart transplantation and. indeed. thoraetc organ 
replacement in general. I think this careiul study of a new drug 
that hit with qUite a splash a year or so ago is another indication 
of the debt that we owe these Investigators. I have a couple of 
comments and then a couple of questions for Dr Armitage. 
In 1981 when cyclosponne was introduced with similar fan-
fare. early results indicated that cyclosporine alone or even 
combined with prednisone was not an adequate regimen. and 
regimens using multiple therapy were developed. In 1983. we 
introduced the triple-therapy concept. which you alluded to with 
FK. t~ and others found that this is a much bett~r regimen in 
terms of a lower incidence ot relection and infection and better 
overall survIval. We have employed this regimen In all subse-
quent heart. lung. and heart-lung reetplents and conhnue to iind 
It effecttve. 
In light oi these results. why would you propose that we 
SWItch to FK? We now are observm~ approxlmatelv 80'7r relec-
tlOn-lree surVival at 1 yD~arK and others uSing tnple therapy have 
had at It.''3st SO'7, relectlon-Iree survl\'al at 1 veal' and bevond. We 
have SImIlar rates oi In/echon. and we have never emploved 
Inducllon or Immunoprophvlaxls as you Indicated you had. 
Second. I think an Important concept IS the one you Introduced 
for reiractorv relectlon. This is an exetting and potentIally verv 
important area. although I Jm puzzled by the average election 
fraction ot greater than !l.t>(} in "our reiractorv rejection group. 
This corresponds to uur e'penence. but nonetheless. this may be 
In excIting potential appllcatton lur this drug. 
Third. the bottum line lor anv 01 thlD~ regimens IS what their 
Impact wIll be on coronan: artcrv dlsea~K This is sttll the malor 
long-term Impediment to survIVal. Based on euher m\'eslIga-
tlOnal or clinical grounds. what are vour Initial impreSSions 
(oncernlng anv adyantal1;l' 01 this agent over the regImens we use 
todav? 
DR ARMITAGE: I olpprectate vour comments verv much. I 
would not encourage ~v~ryone to switch immediatelv 10 this 
drug. It is difficult to make an Impact on the survtval curves that 
we have nowadays. and th~ survtval curves with this agent are 
similar to the v~ry good surVIVal curves produced by any other 
center uSing cyclosponne. No immunosuppressIVe agent IS to be 
used in a cookbook fasluon. and certallUV with this agent there 
was a learning curve aSSOCl,lIed WIth its use. 
Ann Thorac pu~ 
1992:5-1:205-11 
diagnosIs of heart and lung rejection: heart relectton studv 
group. I Heart Transplant 1990;9:587-97. -
7. Kusne S. Dummer IS. Singh N. et al. Infections after liver 
transplantation: an analysis of lot consecutive cases. Medi-
cine 1988:67:132-13. 
8. Kormos RL. Armitage 1M. Dummer IS. Miyamoto. Griffith 
BP. Hardesty RL. Optimal penoperative immunosuppres_ 
sion in cardiac transplantation USing rabbit antithvmocyte 
globulin. Transplantation 1990:49:306-11. 
9. Armitage JM. Kormos RL. Stuart RS. et al. Posttransplant 
Iymphoproliferative disease in thoraetc organ transplant pa-
tients: ten years of cyclosporine-based immunosuppression. 
J Heart Lung Transplant 1991:10:877-87. 
10. Dew MA. Harris R. Simmons RL. Roth L. Armitage 1M. 
Griffith BP. Quality of life advantages of FK 506 "ersus 
conventional immunosuppressive drug therapy In cardiac 
transplantation. Transplant Proc 1991:23:3061-1. 
One major advantage tor some of these pahents IS the qualitv 
of life. mainly in terms ot side effects. Hypertension. although 
seen. is not so difficult to treat. We have no patients on a regimen 
of double antihypertenSive therapy. as IS frequently seen With 
the cyclosponne group. and this may affect long-term renal 
function. That would be one benefit. 
HirsUtism would not be so bad for myself and other gentlemen 
at my age group. but for a 20-year-old woman. it is a problem. 
,md a few of our pediatric patients were switched from cycle-
sporine for that reason. Hirsutism has not been seen WIth FK 506. 
nor has gingival hyperplasia. Some of the side effects of the drug 
are less troublesome. which may have some benefit in terms of 
quality of life. but it is difficult to have an impact on survival 
when we are doing so well already. I think the attempt IS to 
improve the quality of life. and this agent may have some beneilt 
in that realm. 
Regarding coronar\' arterv disease. the inetdence oi coronary 
Jrteriopathy after transplantation In our FK group IS actuallv a 
little high. although not outSide the norm. One concern about the 
drug was that In animal studies. 11 was seen to cause vasculitis in 
IJrgeanlmals. and part oi the reason that It was nut tned in manv 
other centers. I think. was the concern that It would produce 
coronarv vasculitis. We have not seen that or anv other svstemlc. 
muscular. or central nervous systl'm vasculitis. I think the hope 
that FK 506 Will diminish or preclude the e"ent 0/ coronarv 
grt~nopathv IS a talse hupe. as It was tor c\'closponne. One or the 
predictors that Wt.' have sl!t.'n tor the negative l'\1stence ot 
(oronarv artenopathv IS treatment lor rell'CtIOn. Is it worlhwhile 
giVing patients a doSt.' ul sterOIds or pulse therapy tI months. 9 
months. and 12 months postoperattwlv even II they ha\'e not 
had an episode oj rl!ll'Ctlon ttl trv and address thiS Issue at 
Jrtenopathy alter transplantation? 
Regarding the rescue group. although ewctlon Iractlons were 
not diminished In all of the pattents. many 01 them had had 
episodes 01 diminished erection rractlon. Most had bet.'n able to 
maintain adequate "entncular lunCtlon With traditional rescue 
olgents but were unable to clear the cellular response ot relecnon. 
which was achieved with FK 506. I think that It can be an enect1ve 
rescue agent. and when 11 is avadable. I think it will be another 
method by which to treat the problems of the solid-organ 
transplant rectplent. 
OR ,OGINDER N. BHAYANA (Buffalo. NY): I entoved vour 
repon very much. Mv quesbon concerns the rescue therapy. 
----------------------------------
AM Thone Surg 
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Have you seen patients who had rejection with FK 506, and did 
you then try cyclosponne therapy as rescue therapy? 
DR ARM IT AGE: Only 3 patients required rescue therapy. and 
they were treated with OKT3 and had resolution. 
DR JOEL D. COOPER (St. Louis, MO): Mv comments concern 
your ereatinine levels. You reported a me~n creannine level of 
about 2 mg at /) months, which I find very worrisome. How does 
that compare With the ereannine levels of vour historic controls of 
a similar group of patients? Could you c~mment speoficaUy on 
what I conSider a fairly high ereatinine level at 6 months 
poslOperanvelv? 
DR ARMITAGE: There is no question that the drug has neph-
rotoxicitv. We have learned to ameliorate this a little bv dimin-
ishing the intravenous mduction dose, although that ha~ not \'et 
reached slgmficance. I share your concern about the drug's 
nephrotoxlCltV. The learning curves aSSOCIated with theuse 01 the 
drug are verv SimIlar to those ior cvclosponne, and if vou look at 
the early expenence With c\'c1osponne. similar rises In ereahnine 
levels and decreases In renal function were seen, Once agaan. the 
earlv attempts were made to trY to use the drug as a sole agent. 
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[ think perhaps that is a mistake and that it can best be used with 
adjuvant agents. 
One thing I did not mention. mainly because this presentation 
was about adult panents, is that the drug has a major immune 
advantage in pediatric patients. Its nephrotoxicity appears to be 
minimal in children. and most children who had heart transplan-
tation with FK 506 immunosuppression are tree Irom nephrotox-
icity and from the use of any other agent. I think a very exciting 
role for this agent IS its use an both heart and lung transplantation 
in children. 
DR COOPER: Is there a significant difference In the creatinine 
level at 6 months between the FK group and the cyclosponne 
group with which you compared it? 
DR ARMITAGE: When we re\'iewed the cases 01 the 40 patients 
undergomg transplantallon at our center beiore the advent of FK 
506 and treated with cyclosponne, the average creatmine level in 
that group was about 1.7. It was about 2.1 in the FK group at 6 
months. That is not a Significant diffl'rence. However. from the 
standpoint 01 renal functIOn, patients tolerate cvclosponne as we 
use It now better than FK 506 as used in this study .. 
